CCA
NAVB

Catalyst Capital Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Catalyst Capital Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-39,500
Closed -$1.64M – 367
2013
Q4 		$1.64M Buy
+39,500
New +$1.55M 0.53% 75

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Catalyst Capital Advisors's NAVB Position: Q1 2014 in Review

Catalyst Capital Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2014, closing a stake of 39,500 shares — an estimated $1.64M sold.

Catalyst Capital Advisors first reported a position in NAVB in Q4 2013 and held it in 1 quarter. The position peaked at $1.64M in Q4 2013. 83 funds tracked by Wall St. Rank hold NAVB as of Q1 2014.

  • Catalyst Capital Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2014 after selling out during the quarter.
  • Catalyst Capital Advisors sold 39,500 Navidea Biopharmaceuticals Inc. shares in Q1 2014, an estimated $1.64M.
  • Catalyst Capital Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2013 and held it in 1 quarter.
  • Catalyst Capital Advisors's Navidea Biopharmaceuticals Inc. position peaked at $1.64M in Q4 2013.
  • 83 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2014.

Based on Catalyst Capital Advisors's 13F filing for Q1 2014, filed 12 May 2014.